Skip to content

Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

Alzheimer Disease | Alzheimer Dementia | Alzheimer Dementia (AD) | Apathy | Apathy in Dementia | Alzheimer s Disease

This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed AD/vascular dementia

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    0 and up

Participation Criteria

Inclusion Criteria:

* Alzheimer's disease or mixed Alzheimer's disease and vascular disease
* MMSE score 10-28 inclusive
* Clinically significant apathy
* Stable dose of psychotropic medication
* Care partner must spend at least 10hrs/week with the participant

Exclusion Criteria:

* Major Depressive Episode
* Clinically significant agitation, delusions, hallucinations
* Currently talking a dopaminergic agent other than methylphenidate
* Failure to clear the TMS adult safety scale (e.g. unapproved pacemakers, metallic implants, history of epilepsy)
* Central nervous system abnormalities (other than Alzheimer's disease) deemed clinically significant by study physician or seizures
* Any condition that in the opinion of the study physician, makes it medically unsafe for the patient to enroll in the trial

Study Location

Sunnybrook Research Institute
Sunnybrook Research Institute
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Study Coordinator

[email protected]
416-480-6100
Study Sponsored By
Sunnybrook Health Sciences Centre
Participants Required
More Information
Study ID: NCT07279740